YOU ARE NOW LEAVING LUMAKRAS.COM
You are about to leave the LUMAKRAS.com website and enter a website operated by a third party. Amgen is not responsible for and does not endorse or control the content contained on this third-party website.
That has spread to other parts of the body or cannot be removed by surgery, and whose tumor is KRAS G12C positive, and who have received at least one prior treatment.1
THE FIRST ONCE-DAILY ORAL TREATMENT FOR PEOPLE LIVING
WITH KRAS G12C POSITIVE NON-SMALL CELL
LUNG CANCER (NSCLC)1
That has spread to other parts of the body or cannot be removed by surgery, and whose
tumor is KRAS G12C positive, and who have received at least one prior treatment.1
Not Chemotherapy2
References: 1. LUMAKRAS® (sotorasib) Patient Information. Thousand Oaks, CA: Amgen 2021. 2. LUMAKRAS® (sotorasib) Prescribing Information. Thousand Oaks, CA: Amgen 2021.